{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T07:54:36Z","timestamp":1774425276903,"version":"3.50.1"},"reference-count":34,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,1,24]],"date-time":"2006-01-24T00:00:00Z","timestamp":1138060800000},"content-version":"vor","delay-in-days":876,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2003,9]]},"abstract":"<jats:p><jats:bold>A<jats:sc>bstract<\/jats:sc>: <\/jats:bold> Myasthenia gravis (MG) in individuals over 40 years of age comprises three groups: early\u2010onset MG with prolonged disease duration, late\u2010onset MG with thymoma, and late\u2010onset of nonthymomatous MG. The clinical features do not differ between the three groups, except that early\u2010onset patients with prolonged disease duration usually have a less severe disease. More than 60% of our MG patients are now more than 50 years of age, often with disease onset after age 40. Although 2 out of the 3 patients in Erb's original description had onset of myasthenic symptoms after age 40, this was apparently infrequent in 1879, when the disease was first identified. Onset of MG after age 40 is now common. For example, in our material, 88\/184 (47.8%) had onset of MG after age 40. Eighteen (20.5%) had a thymoma. The female:male ratio in the early\u2010onset group was 2.4:1, whereas it was 1:1.1 among those with onset after age 40. There was no human leukocyte antigen association for MG with thymoma. Antibodies to the acetylcholine receptor were detected in 88% of sera from nonthymomatous MG and in 100% of those with late\u2010onset MG with thymoma. Antibodies to titin were found in sera from 85.7% of MG patients with thymoma (all age groups) and in 58% of nonthymomatous MG with late onset and acetylcholine receptor antibodies. Late\u2010onset, nonthymomatous MG comprises two subgroups, one corresponding to delayed early onset and one immunologically similar to that seen in patients with MG and thymoma.<\/jats:p>","DOI":"10.1196\/annals.1254.055","type":"journal-article","created":{"date-parts":[[2004,1,15]],"date-time":"2004-01-15T01:04:15Z","timestamp":1074128655000},"page":"424-431","source":"Crossref","is-referenced-by-count":43,"title":["Myasthenia Gravis in Individuals over 40"],"prefix":"10.1111","volume":"998","author":[{"given":"JOHAN A.","family":"AARLI","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FREDRIK","family":"ROMI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GEIR OLVE","family":"SKEIE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"NILS ERIK","family":"GILHUS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,1,24]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"336","article-title":"Zur Casuistik der bulb\u00e4ren L\u00e4hmungen","volume":"9","author":"Erb W.","year":"1879","journal-title":"\u00dcber einen neuen, wahrscheinlich bulb\u00e4ren Symptomencomplex. Arch. Psychiatrie"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/23.2.277"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01665294"},{"key":"e_1_2_5_5_2","first-page":"594","article-title":"Ueber die Erb'sche Krankheit (myasthenia gravis)","volume":"20","author":"Laquer L.","year":"1903","journal-title":"Neurol. Zentralbl."},{"key":"e_1_2_5_6_2","first-page":"597","article-title":"Patologisch\u2010anatomischer Beitrag zur Erb'schen Krankheit (myasthenia gravis)","volume":"20","author":"Weigert C.","year":"1903","journal-title":"Neurol. Zentralbl."},{"issue":"23","key":"e_1_2_5_7_2","first-page":"1","article-title":"Myasthenia gravis: an analysis of 295 cases","volume":"42","author":"Simpson J.F.","year":"1966","journal-title":"Acta Neurol. Scand."},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1953.02940310038009"},{"key":"e_1_2_5_9_2","first-page":"497","article-title":"Studies in myasthenia gravis: a review of a twenty\u2010year experience in over 1200 patients","volume":"38","author":"Osserman K.E.","year":"1971","journal-title":"Mt. Sinai J. Med."},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1984.tb00825.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.9.1779"},{"key":"e_1_2_5_12_2","doi-asserted-by":"crossref","unstructured":"Osterman P. 1990. Current treatment of myasthenia gravis.InProgress in Brain Research pp. 151\u2013161. Elsevier Science. Oxford.","DOI":"10.1016\/S0079-6123(08)60899-7"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1991.00530190081019"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/103.3.579"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.40.5.786"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1995.tb00432.x"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.64.1.78"},{"key":"e_1_2_5_18_2","unstructured":"Aarli J.A. 1994. Myasthenia gravis and thymoma.InHandbook of Myasthenia Gravis and Myasthenic Syndromes pp. 207\u2013224. Dekker. New York."},{"key":"e_1_2_5_19_2","doi-asserted-by":"crossref","unstructured":"Newsom\u2010Davis J. A. Vincent & N. Willcox. 1982. Acetylcholine receptor antibody: clinical and experimental aspects.InReceptors Antibodies and Disease. Ciba Foundation Symposium. Vol. 90 pp. 225\u2013247. Pitman. London.","DOI":"10.1002\/9780470720721.ch13"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.1997.tb00335.x"},{"key":"e_1_2_5_21_2","first-page":"357","article-title":"Anti\u2010acetylcholine receptor antibodies in myasthenia gravis","volume":"58","author":"Limburg P.C.","year":"1983","journal-title":"I. Relation to clinical parameters in 250 patients. J. Neurol. Sci."},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02337460"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.26.11.1054"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004150050604"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198209233071301"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1990.tb05440.x"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.8.1581"},{"key":"e_1_2_5_28_2","doi-asserted-by":"crossref","unstructured":"Skeie G.O.et al.1995. Titin antibodies in patients with late onset myasthenia gravis: clinical correlations. Autoimmunity 20: 99\u2013104.","DOI":"10.3109\/08916939509001933"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.58.6.885"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410320419"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.57.7.843"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-201x.2001.00841.x"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.56.4.457"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.9.1555"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1331.2002.00352.x"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1196%2Fannals.1254.055","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1196\/annals.1254.055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T17:23:54Z","timestamp":1695662634000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1196\/annals.1254.055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,9]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,9]]}},"alternative-id":["10.1196\/annals.1254.055"],"URL":"https:\/\/doi.org\/10.1196\/annals.1254.055","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,9]]}}}